Response from the CEO about Tigris The trial in no way is halted. Dr. Kellum re-iterated the 30 patients from our last disclosure date. This conference is not considered broad enough distribution to provide the updated enrollment numbers, and falls more into a potential selective disclosure situation. We release our Q1/22 next week, and will provide as usual the corporate update at that time.